未知生产厂商
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
CYNK-001 has the potential to inhibit viral infection by killing host cells through indirect immune responses. CYNK-001 expresses NKG2D and DNAM-1 receptors in addition to cytotoxicity receptors NKp30, NKp44, and NKp46. These receptors bind to the ligands and antigens expressed on infected cells, and initiate the release of perforin and granzyme B from the NK cell to induce cell death. In addition to being investigated for the treatment of acute myeloid leukemia, multiple myeloma, and glioblastoma multiforme, CYNK-001 is also being investigated for treating COVID-19.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
